Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $15.01, but opened at $14.56. Capricor Therapeutics shares last traded at $16.04, with a volume of 1,971,364 shares trading hands.

Analyst Ratings Changes

A number of brokerages recently commented on CAPR. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Capricor Therapeutics Trading Up 14.9 %

The stock has a market capitalization of $551.64 million, a price-to-earnings ratio of -18.44 and a beta of 3.92. The stock’s 50 day moving average is $5.21 and its 200 day moving average is $5.42.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.14 EPS for the current year.

Insider Activity

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at about $426,000. Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.